NCT07424404 Xanomeline Tartrate/Trospium Chloride Autism Spectrum Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07424404 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 24 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07424404 is a hot trial to watch
Autism Spectrum Disorder is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07424404 is notable because it evaluates Xanomeline Tartrate/Trospium Chloride in a Phase 3 design sponsored by Karuna Therapeutics, Inc.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07424404 |
| Official title | A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively |
| Phase / status | Phase 3 / Recruiting |
| Intervention | Xanomeline Tartrate/Trospium Chloride |
| Sponsor | Karuna Therapeutics, Inc. |
| Geography | Canada, Argentina, Romania, Hungary, United States, Japan, Poland, France, Australia, Germany, Spain |
| Enrollment | [object Object] |
| Primary endpoint | Number of participants with treatment emergent adverse events (TEAEs) |
| Endpoint time frame | Up to 54 weeks |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
The purpose of this study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in adolescents, respectively
Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Single Group Assignment. Planned enrollment of [object Object] participants across Canada, Argentina, Romania, Hungary, United States, Japan, Poland, France, Australia, Germany, Spain shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Number of participants with treatment emergent adverse events (TEAEs) (Up to 54 weeks)
- Number of participants with adverse events of special interest (AESIs) (Up to 54 weeks)
- Number of participants with serious adverse events (SAEs) (Up to 54 weeks)
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Xanomeline Tartrate/Trospium Chloride is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.
Company & Deal Intelligence MCP profile: Karuna Therapeutics, Inc. is resolved to a normalized organization record in SUFFOLK COUNTY, United States. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07424404 provides a focused lens on Autism Spectrum Disorder development. Its value will be determined by whether Xanomeline Tartrate/Trospium Chloride can convert the current Phase 3 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
